Summary
For Year 2026-27, Genomic Valley Biotech reports the following shareholding: Total Promoters at 46.06%, Mutual Fund at 0%, Insurance at 0%, Foreign Institutional Investors at 0%, Domestic Institutional Investors at 0%, and Retail at 53.94%. This breakdown provides a quick snapshot of ownership distribution for Genomic Valley Biotech in 2026-27.
Genomic Valley Biotech FAQs
As of 04-2026, the promoter shareholding in Genomic Valley Biotech stands at 46.06% of the company's total shares. Promoter shareholding represents the ownership stake held by the company's founding members, management, or controlling entities, having a significant influence on the company's strategic direction and operations.
The FII and DII shareholding of Genomic Valley Biotech is 0% and 0% respectively.
The retail shareholding of the Genomic Valley Biotech is 53.94%.
Changes in shareholding patterns of Genomic Valley Biotech can result from stock market transactions, issuance of new shares, buybacks, mergers, acquisitions, or changes in promoter holdings.
Shareholding patterns of Genomic Valley Biotech are updated quarterly as mandated by regulatory authorities and may also be disclosed during significant corporate events.
The latest shareholding pattern is available on stock exchanges (e.g., NSE, BSE) and the company's official website under investor relations.
Genomic Valley Biotech Associated Pages
